INTRODUCTION {#s1}
============

Melanoma continues to be a major health burden worldwide \[[@R1], [@R2]\]. Effective removal of the tumor at an early stage remains the only reliable curative treatment. Although an impressive number of new systemic therapeutic approaches have become available in recent years \[[@R3]--[@R9]\], the long-term outlook for patients with metastatic disease remains poor.

A number of landmark genetic studies, primarily focusing on analyzing protein coding genes, have identified a large number of recurrently mutated genes in melanoma \[[@R10], [@R11]\]. In contrast to previously recognized mutations such as *BRAF* and *NRAS*, most of these genes are mutated less frequently (i.e. *NF1*, *RAC1*, *ARID1A*, etc.); their function and the clinical implications of these mutations are still poorly understood.

Recent efforts have moved beyond focusing primarily on protein coding genes and have identified mutations in non-protein coding areas. Potentially the most relevant such mutation identified to date was the finding of *TERT* promoter mutations in a large proportion of melanoma samples (30--70%) \[[@R12], [@R13]\]. These mutations were found to generate novel transcription factor binding sites increasing telomerase expression and have been associated with poor prognosis \[[@R14]\]. In search of novel recurrent mutations that alter transcription factor binding sites, Weinhold et al. recently reported recurrent mutations of the succinate dehydrogenase complex subunit D (*SDHD*) promoter in melanoma \[[@R15]\].

*SDHD* is one of two mitochondrial transmembrane subunits of the four-subunit succinate dehydrogenase (SDH) protein. SDH is an enzyme with two important functions. First, it acts as part of the citric acid cycle converting succinate to fumarate. Succinate functions as an oxygen sensor in the cell and stimulates cell growth in a hypoxic environment, in particular by stabilizing hypoxia-inducible factor (HIF), which controls several genes involved in cell division and the formation of new blood vessels \[[@R16]--[@R18]\]. Loss of SDH enzyme activity can lead to abnormal hypoxia signaling, leading to proliferation and tumor formation. The second known function of SDH is oxidative phosphorylation, an important process for the cell\'s energy budget.

Mutations in *SDHD* have been described in gastrointestinal stromal tumor (GIST) \[[@R19]\], paraganglioma \[[@R20], [@R21]\] and pheochromocytoma \[[@R22], [@R23]\]. Promoter mutations of *SDHD* in 13 of 128 (10%) melanomas were recently described by Weinhold et al. in a genome-wide analysis screening for mutations in noncoding regulatory regions of the DNA \[[@R15]\]. All three described recurrent hotspot mutations in the *SDHD* promoter region substitute a cytosine for a thymine nucleotide (C\>T). The mutations are located at chr.11:111,957,523 (TTCC\>TTTC), chr.11:111,957,541 (TTCC\>TTTC) and chr.11:111,957,544 (CTTCC\>TTTCC). The TTCC response element is highly conserved for E26 transformation-specific (ETS) transcription factors. The mutations alter existing ETS binding motifs predicted to lead to a reduced expression of the *SDHD* gene.

The aim of our study was to further evaluate the incidence of *SDHD* promoter mutations in a large cohort of melanoma samples of various subtypes and to investigate associations of *SDHD* mutation status with clinico-pathologic variables and other common oncogenic mutations in melanoma, such as *BRAF*, *NRAS*, *KIT* and *TERT* promoter mutations.

RESULTS {#s2}
=======

Tumors and patients {#s2_1}
-------------------

The *SDHD* promoter was successfully sequenced in 451 melanoma samples available for analysis, including 223 non-acral cutaneous, 38 acral, 33 mucosal, 43 occult, 43 conjunctival and 51 uveal melanoma samples. Based on lack of detected *SDHD* promoter mutations (addressed below), the 51 primary uveal melanoma samples were excluded from further statistical analyses. The 400 non-uveal melanoma samples included 167 primary tumors, 158 metastases, 5 recurrences, 43 occult and 27 not-classified tumor samples. The samples originated from 230 male and 170 female patients with a median age of 60 years (range 12--90 years) and a median follow-up time of 30 months (range 0.3--375 months) The clinico-pathologic information is summarized in Table [1](#T1){ref-type="table"}.

###### Characteristics of all tumor samples in regard to *SDHD* promoter status (*n* = 400)

  All samples                                                                                                                                                        
  --------------------------------------------------------- -------------------------------------------------- ----------- ------ --------- ------- ------- -------- ------
  Sex                                                       Female                                             170         42.5   163       *41*    7       *2.3*    0.98
                                                            Male                                               230         57.5   221       *55*    9       *1.7*    
  Age at Diagnosis                                          Median                                             60                                                    
                                                            Range                                              12--90                                                
                                                            \<=60 years                                        191         47.5   174       *44*    6       *1.5*    0.45
                                                            \>60 years                                         172         42.8   174       *44*    7       *1.8*    
                                                            Missing data                                       39          9.7    36        *9*     3       *0.8*    
  Mutant oncogene[\*\*](#tfn_003){ref-type="table-fn"}      WT                                                 150         40     145       *39*    5       *1.3*    0.89
                                                            *BRAF[\*](#tfn_002){ref-type="table-fn"}*          142         38     n = 134   *35*    8       *2*      
                                                            *NRAS[\*](#tfn_002){ref-type="table-fn"}*          82          22     79        *21*    3       *0.8*    
                                                            *KIT*                                              4           1      4         *1*     0       *0*      
                                                            TERT prom. WT (underscribt)                        115         55     112       *53*    3       *1.4*    0.38
                                                            *TERT* prom. mut                                   95          45     89        *42*    6       *2.9*    
  *BRAF* and *NRAS*                                         Either mutant[\*](#tfn_002){ref-type="table-fn"}   222         59     n = 211   *56*    11      *2.9*    0.42
                                                            Both WT                                            154         41     149       *40*    5       *1.3*    
  Stage at diagnosis[^\#^](#tfn_001){ref-type="table-fn"}   I                                                  46          12     44        *11*    2       *0.5*    0.88
                                                            II                                                 122         31     118       *30*    4       *1*      
                                                            III                                                122         31     118       *30*    4       *1*      
                                                            IV                                                 29          7      27        *7*     2       *0.5*    
                                                            Missing data                                       81          20     77        *19*    4       *1*      
  Anatomic distribution of primary                          Non-acral skin                                     223         56     214       *54*    9       *2.3*    0.9
                                                            Acral                                              38          10     38        *9*     0       *0*      
                                                            Mucosal                                            33          8      32        *8*     1       *0.3*    
                                                            Occult                                             43          11     40        *10*    3       *0.8*    
                                                            Eye (conj.)                                        43          11     42        *11*    1       *0.3*    
                                                            Missing data                                       20          5      18        *5*     2       *0.5*    
  Anatomic site of skin and acral tumors                    Head & neck                                        n = 40      10%    n = 39    9.8%    1       *0.3*    0.5
                                                            Upper limbs                                        23          6      22        *6*     1       *0.3*    
                                                            Trunk                                              n = 94      24     n = 88    *22%*   n = 6   *1.5%*   
                                                            Lower limbs                                        64          16     63        *16*    1       *0.3*    
                                                            Acral                                              38          10     38        *10*    0       *0*      
                                                            Occult                                             43          11     n = 40    *9*     3       *0.8*    
                                                            Missing data                                       n = 22      6      n = 20    *5%*    2       *0.5*    
  Histologic type                                           ALM                                                30          8      29        *7*     1       *0.3*    0.9
                                                            LMM                                                4           1      4         *1*     0       *0*      
                                                            NM                                                 77          23     75        *19*    2       *0.5*    
                                                            SSM                                                46          12     43        *11*    3       *0.8*    
                                                            Unclassified                                       243         61     233       *58*    10      *2.1*    
  Breslow thickness                                         Median                                             3                                                     
                                                            Range                                              0.1--55.0                                             
                                                            0.01--1.00mm                                       36          9      34        *8,5*   2       *0.5*    0.58
                                                            1.01--2.00mm                                       42          11     39        *10*    3       *0.8*    
                                                            2.01--4.00mm                                       82          21     80        *20*    2       *0.5*    
                                                            \>4.00mm                                           93          24     91        *23*    2       *0.5*    
                                                            Missing data                                       147         37     140       *35*    7       *1.8*    
  Clark level (skin tumors only)                            I                                                  0           0      0         *0*     0       *0*      0.89
                                                            II                                                 5           2      5         *2*     0       *0*      
                                                            III                                                37          17     34        *15*    3       *1.3*    
                                                            IV                                                 74          33     72        *32*    2       *0.9*    
                                                            V                                                  21          9      20        *9*     1       *0.5*    
                                                            Unknown                                            86          22%    n = 83    *21%*   3       *1.3*    
  Sample type sequenced                                     Primary                                            167         42     163       *41*    4       *1*      0.34
                                                            Metastasis                                         158         40     149       *37*    9       *2.3*    
                                                            Recurrence                                         5           1      5         *1*     0       *0*      
                                                            Occult                                             43          11     40        *10*    3       *0.8*    
                                                            Missing data                                       27          7      27        *7*     0       *0*      
  Ulceration                                                Absent                                             62          16     59        *15*    3       *0.8*    0.48
                                                            Present                                            88          22     87        *22*    1       *0.3*    
                                                            Unknown                                            250         63     238       *60*    12      *3.1*    
  SLN                                                       Negative                                           78          20     75        *19*    3       *0.8*    0.97
                                                            Positive                                           84          21     81        *20*    3       *0.8*    
                                                            Not done                                           238         60     228       *57*    10      *2.5*    

WT = wild-type; mut = mutant; ALM = acral lentiginous melanoma; NM = nodular melanoma; SSM = superficial spreading melanoma; LMM = lentigo maligna melanoma; SLN = sentinel lymph node; conj. = conjunctival; prom. = promoter

*p*-values are derived from chi-squared or Fisher exact tests, as appropriate

Staging according to the American Joint Committee on Cancer (AJCC) Melanoma Staging System 2009\[[@R37]\]

2 cases harbored a *BRAF* and a *NRAS* mutation.

*BRAF, NRAS, KIT* were screened in *n* = 376; the *TERT* promoter in *n* = 210 cases

Oncogene mutations {#s2_2}
------------------

*BRAF* mutations occurred in 38% (142/376) of the tumor samples, including 128 (90%) V600E and 8 (6%) V600K. Additionally, individual (1%) V600G, V600D, K601N, K601E, G469A and D594N mutations were identified. *NRAS* mutations were found in 82 (22%) tumor samples, including 37 (45%) Q61R, 25 (25%) Q61K, 14 (17%) Q61L, 4 (5%) Q61H and 2 (1%) G12D mutations. *KIT* mutations were found in 4 (1%) cases. *TERT* promoter mutations occurred in 95 of 210 analyzed cases (45%), including 52 (55%) chr.5:1,295,250C\>T, 31 (33%) chr.5:1,295,228C\>T, 11 (12%) chr.5:1,295,242_1,295,243CC\>TT and 1 (1%) chr.5:1,295,228_1,295,229CC\>TT mutations (Table [1](#T1){ref-type="table"}).

*SDHD* promoter mutation analysis {#s2_3}
---------------------------------

ETS binding site affecting *SDHD* promoter mutations were identified in 16 of 400 tumors (4%), obtained from 7 female and 9 male patients. Eleven mutations were identified at the previously described locations \[[@R15]\]: chr.11:111,957,523 (TTCC\>TTTC), chr.11:111,957,541 (TTCC\>TTTC) and chr.11:111,957, 544 (CTTCC\>TTTCC). Furthermore, we found five mutations occurring at two hotspots (Figure [1](#F1){ref-type="fig"}) located at chr.11:111,957,542 (TTCC\>TTCA) and chr.11:111,957, 547 (CTTCC\>CTTTC or CTTCC\>CCTAC), which were not yet described, but also result in sequence alterations of the ETS-binding element (Figure [1](#F1){ref-type="fig"}). In the remaining manuscript, only the last three digits of the chromosome location nomenclature will be used for annotating the mutations location (i.e. 523C\>T). The *SDHD* promoter mutations identified included 5 (1.3%) 523C\>T cases, 3 (0.8%) 541C\>T, 3 (0.8%) 542C\>A, 3 (0.8%) 544C\>T cases, 1 (0.3%) 547C\>T and 1 (0.3%) 547C\>A case (Table [2](#T2){ref-type="table"}).

![Recurrent *SDHD* promoter mutations altering ETS binding elements\
Sanger sequencing chromatograms of the identified recurrent *SDHD* promoter mutations located at chr.11:111,957,523C\>T(TT[C]{.ul}C\>TTT[C]{.ul}), chr.11:111,957,541C \> T (TT[C]{.ul}C\>TT[T]{.ul}C), chr.11:111,957,544C\>T ([C]{.ul}TTCC\>[T]{.ul}TTCC), chr.11:111,957,542C\>A (TTC[C]{.ul}\>TTC[A]{.ul}) and chr.11:111,957,547 (CTT[C]{.ul}C\>CTT[T]{.ul}C and CTT[C]{.ul}C\>CTT[A]{.ul}C) (according to human genome assembly \[hg19\]). The mutations locations are highlighted with black arrows. A wild-type promoter sequence for comparison is shown on the top. The blue boxes in the wild-type *SDHD* promoter sequence show the three different ETS binding elements. \* signifies the mutation also identified in a germ-line sample.](oncotarget-06-25868-g001){#F1}

###### *SDHD* promoter mutations in association to clinico-pathologic variables

  Affecting ETS domains                                             Not affecting ETS domains                                                    
  ----------------------------------------------------------------- --------------------------- --- --- --- --- --- ---- ------- --- --- --- --- -----
  Sex                                                               Female                      1   3   2   0   1   0    7       0   1   1   1   3
                                                                    Male                        4   0   1   3   0   1    9       1   1   0   0   2
  DNA type                                                          Primary                     3   1   0   0   0   0    4       0   0   0   0   0
                                                                    Metastasis                  2   2   1   3   1   0    9       1   1   1   1   4
                                                                    Occult                      0   0   2   0   0   1    3       0   0   0   0   0
                                                                    Missing data                0   0   0   0   0   0    0       0   1   0   0   1
  Mutant oncogene                                                   *BRAF*                      2   1   2   2   1   0    8       0   0   1   0   1
                                                                    *NRAS*                      1   0   0   1   0   1    3       0   0   0   0   0
                                                                    *KIT*                       0   0   0   0   0   0    0       0   0   0   0   0
                                                                    *TERT* prom. mut            0   2   2   2   0   0    6       1   1   1   0   3
  *BRAF* and *NRAS*                                                 Either mutant               3   1   2   2   1   0    9       0   0   1   0   1
                                                                    Both WT                     2   2   1   1   0   1    7       1   2   0   1   4
  Clinical stage at diagnose[^\#^](#tfn_004){ref-type="table-fn"}   I                           1   0   0   1   0   0    2       0   0   0   0   0
                                                                    II                          0   3   0   1   0   0    4       1   1   1   0   3
                                                                    III                         2   0   1   1   0   0    4       0   0   0   1   1
                                                                    IV                          0   0   1   0   0   1    2       0   0   0   0   0
                                                                    Missing data                2   0   1   0   1   0    4       0   1   0   0   1
  Anatomic distribution of primary                                  Non-acral                   3   3   1   2   0   0    9       1   1   1   1   4
                                                                    Acral                       0   0   0   0   0   0    0       0   0   0   0   0
                                                                    Mucosal                     0   0   1   0   0   0    1       0   0   0   0   0
                                                                    Occult                      0   0   1   1   0   1    3       0   0   0   0   0
                                                                    Eye (conj.)                 1   0   0   0   0   0    1       0   0   0   0   0
                                                                    Missing data                1   0   0   0   1   0    2       0   1   0   0   1
  Germline                                                          Analyzed samples            4   1   3   2   1   1    12/16   0   2   1   1   4/5
                                                                    Mutant (+/−)                −   −   −   −   −   \+           −   −   −   −   

WT = wild-type; mut = mutant; prom. = promoter; conj. = conjunctival

Staging according to the American Joint Committee on Cancer (AJCC) Melanoma Staging System 2009\[[@R37]\]

In addition to the ETS binding site affecting mutations, *SDHD* promoter mutations not affecting the ETS binding elements were identified in 5 tumor samples. These mutations included individual chr.11:111,957,529 (TTCA\>TTTA), chr.11:111,957,550 (CCCT\>CCCA) and chr.11:111,957,556 (TTCT\>TTTT) mutations, as well as two chr.11:111,957,538 (TTTCC\>ATTCC) mutations (Figure [2](#F2){ref-type="fig"}).

![*SDHD* promoter mutations outside of ETS binding elements\
Sanger sequencing chromatograms of the identified *SDHD* promoter mutations located at chr.11:111,957,529 (TT[C]{.ul}A\>TT[T]{.ul}A), chr.11:111,957,538 ([T]{.ul}TTCC\>[A]{.ul}TTCC) chr.11:111,957,550 (CCC[T]{.ul}\>CCC[A]{.ul}), and chr.11:111,957,556 (TT[C]{.ul}T\>TT[T]{.ul}T) (according to human genome assembly \[hg19\]). The location of the mutations is highlighted with black arrows. The top chromatogram demonstrates a wild-type promoter sequence for comparison. The blue boxes in the wild-type *SDHD* promoter sequence show the three different ETS binding elements.](oncotarget-06-25868-g002){#F2}

None of the 51 uveal tumor samples analyzed harbored a *SDHD* promoter mutation.

Germline *SDHD* promoter analysis {#s2_4}
---------------------------------

For tumors in which *SDHD* promoter mutations were identified, matching constitutional DNA from peripheral blood mononuclear cells was analyzed if available. This was the case in 12 of the 16 tumors with *SDHD* promoter mutations affecting ETS binding sites and 4 of 5 tumor samples with *SDHD* promoter mutations not affecting ETS binding sites. One of the ETS binding site affecting mutations (547C\>A) was found to be present in the germline (Figure [3](#F3){ref-type="fig"}). In all other cases, *SDHD* promoter mutations detected in the tumor were not present in the constitutional DNA, confirming they were acquired somatically (Table [2](#T2){ref-type="table"}).

![Germ-line *SDHD* promoter mutation\
Sanger sequence chromatograms show a chr.11:111,957,547C \> A *SDHD* promoter mutation present both in the patient\'s melanoma sample as well as the germ-line. PBMC = peripheral blood mononuclear cells.](oncotarget-06-25868-g003){#F3}

Clinico-pathologic correlations of *SDHD* promoter mutant tumors {#s2_5}
----------------------------------------------------------------

For the analyses presented in the paper, only those *SDHD* promoter mutations affecting the ETS domains were deemed to be relevant (*n* = 16). However, no significant differences were observed when the samples harboring *SDHD* promoter mutations not affecting ETS binding domains were also included in the analysis (data not shown).

ETS binding site affecting *SDHD* promoter mutations were detected in 9 metastatic and 4 primary tumor samples (Table [1](#T1){ref-type="table"}). Non-acral cutaneous melanomas harbored 9 of the 16 mutations (56%). One mutation each was found in a conjunctival and mucosal melanoma tumor sample. Three mutations occurred in occult tumor samples and in two cases anatomic site information was not available (Table [2](#T2){ref-type="table"}). Of the 5 *SDHD* promoter mutations not affecting the ETS binding domains, 4 were in metastatic samples of non-acral cutaneous melanoma. No anatomic site information was available for the remaining case.

No statistically significant associations of *SDHD* promoter mutation status with available clinical parameters including stage at diagnosis, Breslow thickness, Clark level, presence of ulceration, histologic type and mutation status (*BRAF, NRAS, KIT, TERT* promoter) were identified (Table [1](#T1){ref-type="table"}, [Supplemental Table 1 + 2](#SD1){ref-type="supplementary-material"}). This was the case regardless of whether selectively ETS binding site mutations (Table [1](#T1){ref-type="table"}) or all identified mutations were considered (data not shown).

In our cohort, 123 patients died, on average 52 months (range 2--375) after diagnosis. Six patients with *SDHD* promoter mutation died during the follow-up period. A statistically significant association between *SDHD* promoter mutation and overall survival was not found (Figure [4](#F4){ref-type="fig"}).

![Survival based on stage at diagnosis and *SDHD* promoter mutation status\
Kaplan-Meier curves of overall survival in 400 patients with melanoma according to **A.** stage at diagnosis; **B.** *SDHD* promoter status (mutant vs wild-type).](oncotarget-06-25868-g004){#F4}

*SDHD* promoter mutations in existing exome data {#s2_6}
------------------------------------------------

To explore the general frequency of *SDHD* promoter mutations and potential relevance for therapy resistance in melanoma, we re-analyzed exomes sequenced from 69 melanoma patients under MAPKi therapy \[[@R24]\]. DNA outside the targeted coding regions can be assessed if pulled down along with the targets during the capture process. Of 183 available exomes, sufficient coverage in the *SDHD* promoter region was obtained in 126 (69%) cases (min. 10x, max. 72.8x, average 22.7x). In the 92 tumor exomes with sufficient coverage we detected 4 *SDHD* promoter variants (4.3%, [Supplemental Table 3](#SD1){ref-type="supplementary-material"}). No mutations were detected in germline samples.

DISCUSSION {#s3}
==========

In our study of a large cohort of ocular, cutaneous, mucosal and occult melanomas, *SDHD* promoter mutations affecting recurrent ETS binding elements were identified in only 4% (16/400) of the samples. Most mutations detected were at previously reported hotspots (*n* = 11) \[[@R15]\], with a C\>T UV-signature \[[@R25], [@R26]\]. Additionally, 10 other mutations were identified, five of which altered the sequence of ETS transcription factor binding elements. Our study validates the finding of recurrent mutations in the *SDHD* promoter; however these mutations were considerably rarer than previously reported and showed no association with prognosis or the clinico-pathologic variables that were analyzed.

Most of the identified *SDHD* promoter mutations altering the TTCC element of the ETS transcription binding sites were found in one of the three previously described mutation hotspots located at chr.11:111,957,523, chr.11:111,957,541 and chr.11:111,957,544 (Figure [1](#F1){ref-type="fig"}). However, 5 additional mutations were identified at two previously undescribed hotspots, three mutations at Chr.11:111,957,542 (TTCC\>TTCA) and two mutations at Chr.11:111,957,547 (CTTCC\>CTTTC, CTTCC\>CTTAC) (Figure [1](#F1){ref-type="fig"}). All of these newly identified mutations alter the ETS binding site core element (TTCC). In contrast, the previously reported recurrent 544C\>T mutation is located just outside the core element (CTTCC\>TTTCC, Figure [1](#F1){ref-type="fig"}). The altered nucleotide in this setting is conserved in a number of ETS transcription factors including ELF1 \[[@R15]\]. It would appear logical that the various mutations exert differing effects on *SDHD* gene transcription and protein translation. Detailed functional studies will be required to elucidate the extent to which these mutations differ in terms of their effect on transcriptional regulation of *SDHD*.

Mutation frequencies among melanoma subtypes did not vary greatly: non-acral cutaneous 4% (9 of 223), mucosal 3% (1 of 33), acral 0% (0 of 38), conjunctival 2% (1 of 43), occult 7% (3 of 43). The majority of ETS binding site altering *SDHD* promoter mutations (9 of 16 = 56%) were identified in the non-acral cutaneous melanoma. C\>T mutations, which are a marker of UV-exposure, were observed only in these tumors. A single mucosal melanoma (1 of 33, 3%) harbored a 542C\>A alteration; no mutations in acral (*n* = 38) melanomas were identified (Table [2](#T2){ref-type="table"}). In contrast to C\>T mutations, C\>A alterations are not typical for UV induction. Additionally, no mutations were identified in uveal melanoma samples (*n* = 51), a tumor also lacking association with UV exposure \[[@R27]\]. The type of mutations identified does support *SDHD* promoter mutations in UV-exposed tumors (i.e. non-acral cutaneous) being primarily UV-induced, whereas the 542C\>A mutation occurring in a mucosal, non UV-exposed melanoma probably developed in a UV-independent fashion. The overall lack of mutations in uveal melanoma further supports their being genetically distinct from cutaneous, mucosal and conjunctival melanoma \[[@R28]--[@R30]\].

The significance of the 5 *SDHD* promoter mutations identified outside of the three existing ETS binding elements (Figure [2](#F2){ref-type="fig"}) is unclear. Given that melanoma has a particularly high frequency of mutations \[[@R31]\], many of unclear functional relevance, it is possible that the identified alterations are simply passenger mutations. The only recurrent mutation, chr.11:111,957,538 (TTTCC\>ATTCC), identified in two tumors, is located just outside of the ETS core element, similar to the previously described 544C\>T mutation, however resulting in a different sequence (ATTCC versus TTTCC, respectively). Detailed functional studies will be required to determine the significance of these alterations. To exclude the possibility that these mutations might have (as yet unknown) functional importance, all statistical analyses were also performed including all 21 samples with *SDHD* promoter mutations (independent of their known effects on ETS binding sites). The results were similar in that no significant associations with various clinico-pathologic parameters including survival were observed.

The identification of a germline *SDHD* promoter mutation altering the ETS binding site is intriguing. The patient with the 547C\>A germline mutation was a 79-old male presenting with stage IV disease upon initial diagnosis of an occult Melanom, which harbored an *NRAS* Q61K mutation (in addition to the 547C\>A *SDHD* promoter mutation). The patient died of melanoma 4.5 months after diagnosis. Unfortunately, no detailed information on the patient and his family were available. Although the age of the affected patient argues against the role of this mutation in increasing the risk of melanoma, larger numbers of patients will be needed to adequately address this question.

There is a difference in mutation frequency observed between our study (∼4%) and the previous one by Weinhold et al. (10%). This could simply be due to differences in cohort characteristics and sample sizes (Weinhold et al. analyzed 128 samples). Another relevant factor may be the difference in experimental approaches applied. Weinhold et al. analyzed existing next generation sequencing data, searching for recurrent transcription factor mutations in the promoter region of genes, without sequencing validation. Our approach relied on targeted Sanger-sequencing. Both approaches have advantages and disadvantages. Sanger-sequencing does have a detection limit of ∼20%, and the potential to miss low-level mutations. On the other hand, next-generation sequencing approaches are not error-free, and can report incorrect results based on sequencing errors or various bioinformatic analytic hurdles.

To compare our Sanger sequencing results to NGS data, we explored an existing exome dataset detecting *SDHD* promoter variants in ∼4% of tumors. These variants were equally distributed in pre-treatment and recurrent tumors, showing no obvious association of *SDHD* variants with therapy resistance. Filter criteria for NGS analyses probably influenced the higher frequency of *SDHD* promoter variants in Weinhold\'s study. Their Bayesian methods identified the *SDHD* promoter as regionally recurrent in 5′UTRs (5 of 128 samples, with a FDR of 0.0016). However, the unique coverage at mutated positions and mutational frequency in the sequencing reads was not listed. Repeating our analysis without requiring a minimum of 2 unique reads to support a *SDHD* variant, we detected 11 variants in 92 tumors (12%). Strikingly, the additional variants were represented by a single sequencing read each and could likely represent false positives due to sequencing error. Even if one assumes some of the mutation calls could be correct, the question arises what biologic relevance such low frequency mutations may have. We believe that Sanger-sequencing remains a particularly robust form of sequence analysis and should be used whenever possible to confirm the presence of sequence variations before reporting newly-identified mutations.

No association of *SDHD* promoter mutation status with overall survival was seen (Figure [4](#F4){ref-type="fig"}). Admittedly, the number of mutated samples in our cohort is low (*n* = 16, or *n* = 21 if including *SDHD* promoter mutations not affecting ETS binding sites), meaning larger studies will be required to convincingly assess survival. However, Weinhold et al. reported a statistically significant (*p* = 0.005) survival difference with poorer prognosis for *SDHD* promoter mutations analyzing less mutant cases (*n* = 12). Given the discrepancy in our findings and taking into account Weinhold et al.′s relatively small sample size, we believe that the prognostic association of *SDHD* promoter mutations is yet to be unequivocally established and should be explored further in future studies.

It would be interesting to determine to which extent expression levels of SDHD protein are actually affected by *SDHD* promoter mutations. Considering the mutations are assumed to disrupt promoter binding sites, tumors with promoter mutations would be expected to show lower *SDHD* protein expression \[[@R15]\]. As the number of *SDHD* promoter mutated samples we found is very low, one can expect future studies will be required to screen large cohorts of tumors to allow a convincing statistical analysis of promoter mutation status and protein expression to be performed.

Overall, our study validates the finding of recurrent mutations in the *SDHD* promoter, which are enriched for mutations inactivating ETS transcription binding sites. However, in contrast to the initial report, the overall frequency of *SDHD* promoter mutation we identified is low (∼4%) and showed no association with poorer survival. Should these findings be validated in additional cohorts, they argue that compared to the much more frequent and prognostically relevant *TERT* promoter mutations, *SDHD* promoter mutations play a relatively minor role in melanoma.

MATERIALS AND METHODS {#s4}
=====================

Sample selection {#s4_1}
----------------

451 melanoma samples were obtained from patients treated in the Department of Dermatology or Ophthalmology of the University Hospital Essen, Germany. The samples included 223 non-acral cutaneous, 38 acral, 33 mucosal, 43 occult, 43 conjunctival and 51 uveal melanomas (Table [1](#T1){ref-type="table"}). The study was performed in accordance with the guidelines put forth by the ethics committee of the University of Duisburg-Essen.

Clinical and pathologic parameters {#s4_2}
----------------------------------

All clinical and pathologic parameters were obtained from patient records. The following parameters were assessed: sex, age, anatomic location of the tumor, pathologic stage, histologic subtype, Breslow thickness, Clark level, sentinel lymph node status, overall survival, and correlation with other gene mutations (incl. *BRAF*, *NRAS*, *KIT*, *TERT* promoter).

DNA isolation and direct (Sanger) sequencing {#s4_3}
--------------------------------------------

Five ten-micrometer-thick sections were cut from paraffin-embedded tumor tissues and were deparaffinized. Genomic DNA was isolated using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer\'s instructions. Polymerase chain reaction (PCR) was preformed to amplify the *SDHD* promoter region with the following primers: SDHD-F: ACC TTC CGA CAG CTG TGT TT, and SDHD-R: CTC AAG GTC ATC CAC CAA CC amplifying a 151-bp fragment. The PCR products were Sanger sequenced, as previously described \[[@R32]\]. For sequence-data analysis Chromas software was applied (version 2.01, University of Sussex, Brighton, UK). *BRAF* exon 15, *NRAS* exon 1 and 2, *KIT* exon 9, 11, 13, 17, 18 and the *TERT* promoter were PCR amplified and sequenced as previously described \[[@R32], [@R33]\]. Sequencing for *BRAF*, *NRAS* and *KIT* was generally performed sequentially; *NRAS* sequenced in *BRAF* wild-type samples, *KIT* in *BRAF* and *NRAS* wild-type samples. *SDHD* PCR and Sanger sequencing of peripheral blood mononuclear cells (PBMC) derived constitutional DNA was performed in 15 patients with *SDHD* promoter mutated tumor samples. DNA was isolated from PBMC, as described previously \[[@R34]\].

Statistical analyses {#s4_4}
--------------------

Associations of *SDHD* promoter mutations and clinico-pathologic variables, such as age, sex, primary tumor location, TNM status, histologic type, mutation status (for *BRAF*, *NRAS*, *KIT* and *TERT* promoter mutations), Breslow thickness, Clark level, ulceration and sentinel lymph node status were explored using chi-square or Fisher exact tests as appropriate. A *p* value \< 0.05 was considered statistically significant. For all statistical analysis, SPSS Statistics software (version 22.0; SPSS Chicago, IL) was applied.

*SDHD* promoter analysis in existing exome data {#s4_5}
-----------------------------------------------

We re-analyzed a dataset of 116 tumor and 67 germline exomes from 69 patients under MAPK inhibition (MAPKi) therapy \[[@R24]\] with respect to the *SDHD* promoter region. Bam files were indexed using samtools \[[@R35]\] and the hg19 human genome reference. Coverage was obtained using samtools-1.0 mpileup and the unix tools awk \[[@R36]\] and sed (<http://www.gnu.org/software/sed/>). Variant calls were performed using samtools-1.0 mpileup and bcftools query at positions 111,957,519 to 111,957,551 of chromosome 11 (32bp). A minimum average coverage of 10 unique reads across the 32bp region of the *SDHD* promoter was required and variants called when supported by at least 2 unique sequence reads.
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NGS

:   next generation sequencing

ETS

:   E26 transformation-specific

SDHD

:   Succinate dehydrogenase complex subunit D
